Navigation Links
Anti in Biological Technology

FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c

- New labeling reinforces strong safety profile of Ranexa - - Conference call scheduled for 8:00 a.m. ET/5:00 a.m. PT - PALO ALTO, Calif., Nov. 6 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX ) announced today that the U.S. Food and Drug Administration (FDA) has approved a ...

Sanofi-aventis Announces Second Quarter 2009 Results

...tember 1. Results from the SEPIA-ACS1 TIMI 42 phase II trial, evaluating the efficacy and tolerance of otamixaban (an intravenous selective anti Xa factor) in patients with acute coronary syndrome (without ST segment elevation) will also be presented at a plenary session on August 30. ...

SIRO Group Appoints Scott L. Spector as President, Strategic Operations, for its European Business

... increasing responsibility over a 9-year period, serving as General Manager for their Paris, France office and Global Finance Director for the CNS and anti Infective business units. Mr. Spector played a key role in integrating newly acquired businesses, growing operations, implementing business management...

Preclinical Data From Amgen's Oncology Pipeline to be Presented at AACR

...12:00 pm) -- Involvement of the CSF-1/CSF-1R interaction in the control of angiogenesis Overview: Two different neutralizing rat anti murine CSF-1R monoclonal antibodies (mAb), M279 and AFS98 were evaluated for their effect on mouse corneal angiogenesis and corneal ma...

CV Therapeutics' Board of Directors Rejects Astellas' Tender Offer

...on as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti anginal therapies. CV Therapeutics also has other clinical and preclinical drug development candidates and programs. Additional Information ...

CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas' Tender Offer

...on as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti anginal therapies. CV Therapeutics also has other clinical and preclinical drug development candidates and programs. Additional Information S...

CV Therapeutics' Board of Directors Rejects Astellas Unsolicited Proposal

...on as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti anginal therapies. CV Therapeutics also has other clinical and preclinical drug development candidates and programs. Except for the historical i...

CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results

...on as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti anginal therapies. CV Therapeutics also has other clinical and preclinical drug development candidates and programs. Except for the historical i...

BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update

...yst also presented a poster at ASH entitled, "BCX-4208 (RO5092888), a Purine Nucleoside Phosphorylase (PNP) Inhibitor is a Novel, Potent Orally Active anti T- and B-Cell Agent." Findings presented in this poster support the evaluation of BCX-4208 in the treatment of not only T-cell mediated diseases, but...

CV Therapeutics Statement on Unsolicited Proposal From Astellas

...on as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti anginal therapies. CV Therapeutics also has other clinical and preclinical drug development candidates and programs. Except for the historical ...

BioCryst to Present Three Posters During the 50th American Society of Hematology Annual Meeting and Exposition

...entations at ASH is as follows: BCX-4208 (RO5092888), a Purine Nucleoside Phosphorylase ( PNP ) Inhibitor is a Novel, Potent Orally Active anti T- and B-Cell Agent (Poster # 1547) Saturday, December 6, 2008, 5:30 p.m. - 7:30 p.m. Pacific Time; Hall A A Phase II Study of the Puri...

CV Therapeutics Reports 2008 Third Quarter Financial Results

...on as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti anginal therapies. CV Therapeutics also has other clinical and preclinical drug development candidates and programs. Except for the historical infor...

Savient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference

...ontrol remained relatively constant during extended therapy with pegloticase. - Neutralizing antibodies and clinically relevant titers of anti pegloticase IgE were not present in any of the patients with continued use of pegloticase out to as long as 18 months. These result...

MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology

...anluca Carlesso, Ph.D., Tuesday, October 28 from 9:00 a.m. - 11:00 a.m. in Hall A, Abstract: 1843 -- In vitro properties of CAM-3001, a human anti GM-CSF receptor antibody for the treatment of patients with rheumatoid arthritis - Matthew Sleeman, Ph.D., Tuesday, October 28 from 9:00 a.m...

BioElectronics Corp Aggressively Expands Sales into Middle East

...strong demand for drug-free medical products," said Andrew J. Whelan, CEO of BioElectronics Corporation. "There is well established need for drug free anti inflammatory therapy in the Middle East which we expect to capture and expand." Whelan explained that Dr. Halawy has had significant sales managemen...

Immureboost Inc Announces a Change of Name to Fountain Healthy Aging Inc

... half alone, and to US$70 Billion in the next 3 years. The worldwide global anti aging market is expected to reach US$115.5 Billion by 2010, and is now one ...ing industry sectors worldwide. We have a range of products targeted at the anti aging market, including our revolutionary flagship product Vitalife, which ...

NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING

...expand the use of nimotuzumab from the pediatric population to adults with high grade brain tumors. "Pharmacodynamic (PD) study of Nimotuzumab, an anti epidermal growth factor receptor (EGFR) monoclonal antibody (MAb), in patients with unresectable squamous cell carcinoma of the head and neck (SCCHN...

ULURU Inc. to Present at the 8th World Biomaterials Congress

...to be marketed throughout Europe and other international markets. The initial wound dressing containing an active agent, silver, an anti microbial and anti bacterial agent, has recently completed the necessary GLP toxicology studies and we expect to file for 510k approval with the FDA in the second half o...

Depth of MedImmune's Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society

...Developing Controversies in Clinical Asthma (Poster Session: Safety Profile, Pharmacokinetics and Biologic Activity of a Single IV Dose of the anti IL-5 Receptor Alpha Antibody MEDI-563 in Patients with Mild Asthma, publication page A569)-Tuesday, May 20 from 8:15 a.m.- 11:00 a.m., Metro T...

Sidec Announces the First Protein Tomography(TM) Award at Sidec's Executive Forum at PEGS

... "During PEGS it became obvious that studying molecular mechanisms is indeed a crucial step in antibody development. Even for some of the best studied anti cancer drug targets, such as CD20, a fundamental understanding of the drug mechanisms is still lacking. Hence, Sidec's Protein Tomography(TM) Award fi...

Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research

...d, Lung, Brain/CNS and Sarcoma Session) - Poster session scheduled for Wednesday, April 16, 2008 at 8:00 a.m. -- "Preclinical development of anti B7-H4 therapeutic antibodies" (Abstract #4986, Developmental Immunotherapy Session) - Oral presentation scheduled for Tuesday, April 15, 2008 ...

BioElectronics Announces Canadian Retail Product Launch

... This agreement will usher in a new era for biophysics medicine," said Andrew Whelan, President of BioElectronics. "ActiPatch is a unique drug free, anti inflammatory therapy, which will retail in Canada at market disruptive prices providing therapy for less than $1.50 per day. We are confident and comm...

YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION

...ents is anticipated early in 2008. The poster presentation is entitled "Preliminary Results Of An Escalating Dose (Phase I /II Clinical) Trial Of The anti EGFR Monoclonal Antibody Nimotuzumab In Combination With External Radiotherapy In Patients Diagnosed With Stage IIB, III or IV NSCLC Unsuitable For Ra...

Turbo Tax Online can teach new Web concepts a business lesson

...es design flaws, I can't complain about the ease of use and the ease of mind that this product delivers in straight-forward fashion. TurboTax: The anti 2.0 By no modern definition is TurboTax Online a Web 2.0 product. In fact, some might even scoff that I'd take the time to write about an old pro...

Quantitative Analysis of the Cell Cycle in Imaging Applications

...m/Wash Buffer and stained simultaneously with Alexa Fluor 488 (Invitrogen, A-20000) conjugated anti-BrdU (Cat. No. 555627). Alexa Fluor 647 conjugated anti phospho-Histone H3 (Serine 28) (Cat. No. 558217), and Alexa Fluor 555 (Invitrogen A- 20009) conjugated anti-Ki-67 (Cat. No. 610969) in PBS with 3% FCS...

The use of CypHer5 for receptor internalization studies in both a range of GPCRs and a non-GPCR

...ess of CypHer5 Mono NHS Ester.

3. The final dye:protein (D:P) ratio for CypHer5 labelled anti-EGFR was calculated to be 1.4:1 (the CypHer5 anti VSV-G antibody uses a D:P ratio of between 1.5:1 and 3.0:1 for optimum performance).

4. Labelled antibody should immediately be diluted to...

Detection of antibody-stained cell surface and intracellular protein targets with the Agilent 2100 bioanalyzer

...lcein, the cells were incubated with APC-labeled anti hCD4-antibody. After washing and resuspending ...fixation solution. They were then stained with anti GR antibodies and APC-conjugated secondary ant... Reagents anti hCD3 APC antibody, anti hCD4 APC antibody ...

Apoptosis detection by annexin V and active caspase-3 with the Agilent 2100 bioanalyzer

...atment with camptothecin or by incubation with anti Fas-antibodies. Different readouts were chosen ...t cells were treated for two and four hours with anti Fas antibodies to induce apoptosis. In this ap...f 5 x 105/ml with 1 M camptothecin or 0.5 g/ml anti Fas-antibody for 224 h to induce apoptosis. ...

Detection of mRNAs on Cryosections of the Cardiovascular System Using DIG-Labeled RNA Probes

...SF, type VIII collagen) and immunohistochemical characterization of vascular cells using cell type-specific antibodies (smooth muscle cells: anti smooth muscle actin, Enzo; endothelial cells: von Willebrand factor, Sigma; macrophages: CD68, DAKO) and a peroxidase staining procedure (Vectasta...
Other Tags
(Date:7/21/2015)... Connecticut , July 21, 2015  NXT-ID, ... "Company"), a biometric authentication company focused on the ... Wocket® smart wallet, announces that it has filed ... System and Method. This invention ... not only authorizes an account, but also the ...
(Date:7/13/2015)... , July 13, 2015 Synaptics Inc. ... human interface solutions, today announced sampling of ClearPad ... display driver integration (TDDI) product targeting smartphones and ... to combine Synaptics , best-in-class touch controller ... driver technology developed in the company,s Japan Design ...
(Date:7/9/2015)... , July 07, 2015 ... announced the addition of the "Biometrics for ... Forecasts 2015-2020" report to their offering. ... major contributor to this growth and the forecast ... billion in revenue for companies involved in delivering ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
(Date:7/29/2015)... ... July 29, 2015 , ... We are privileged to announce that U.S. News & World ... ninth best ophthalmology hospital in the nation for 2015-2016. This marks the 21st consecutive year ... , “It is an honor to be included in the top 10 ophthalmology hospitals ...
(Date:7/29/2015)... Angeles, CA (PRWEB) , ... July 29, 2015 ... ... to Honduras with the Hackett Hemwall Foundation in March, Steven W. Meier M.D., ... pro bono prolotherapy treatments to qualifying patients with demonstrated financial need. , “We ...
(Date:7/29/2015)... Wis. (PRWEB) , ... July 29, 2015 , ... ... its first two patients in a Clinical Performance Study for the Invisiport at ... 4.4 and 6 French catheter options, offers a less invasive, patient-friendly alternative to ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... the Judicial Panel on Multidistrict Litigation (JPML), according to court documents.* Attorneys handling ... their website, the Zofran Birth Defects Lawsuit Center. , GlaxoSmithKline, the global pharmaceutical ...
(Date:7/29/2015)... ... 2015 , ... The Woodlands and Spring Fit Body Boot Camps have implemented ... causes each month. The new system will track each time a client uses social ... each facility, the boot camps will donate 20 cents to a selected charity. , ...
Breaking Medicine News(10 mins):Health News:21 Years & Counting: The USC Eye Institute Ranks in the Top 10 Ophthalmology Hospitals in America 2Health News:21 Years & Counting: The USC Eye Institute Ranks in the Top 10 Ophthalmology Hospitals in America 3Health News:Orthopedic Surgeon Announces New Pro Bono Prolotherapy and Regenerative Medicine Clinic for Underserved Communities in Los Angeles 2Health News:Stealth Therapeutics Inc. Enrolls First Patients in a Clinical Performance Study for the Invisiport Product Line 2Health News:Stealth Therapeutics Inc. Enrolls First Patients in a Clinical Performance Study for the Invisiport Product Line 3Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 2Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 3Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 4Health News:Transforming Texan Lives and Bodies: Woodlands and Spring Fitness Boot Camps Commit to Multiple Charity Donations 2Health News:Transforming Texan Lives and Bodies: Woodlands and Spring Fitness Boot Camps Commit to Multiple Charity Donations 3
Other Contents